PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congre...(cellular energetics and improve global c...)

Date:6/3/2009

cellular energetics, and improve global cardiac function. Importantly, ARAs' effects are not mediated by conversion of the drug to adenosine or by any direct activity at the adenosine receptors. Rather, ARAs have been shown to increase endogenous adenosine release in an event-specific and site-specific fashion, remaining pharmacologically silent in the absence of net ATP breakdown.

About PeriCor Therapeutics

PeriCor Therapeutics, Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to improve treatment and patient outcomes in acute-care settings of ischemia/reperfusion injury and heart failure. In August 2007, PeriCor granted worldwide development and commercialization rights for its first generation ARA, acadesine, to Schering-Plough Corporation under a licensing agreement. Last month, Schering-Plough announced the initiation of a Phase III pivotal trial of acadesine, an investigational drug, to reduce serious adverse cardiovascular outcomes associated with CABG surgery.

    Contacts: Richard R. Stover
              PeriCor Therapeutics, Inc.
              212-601-2725

'/>"/>

SOURCE PeriCor Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member